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Abstract 
 
In Bangladesh, despite the official introduction of artemisinin combination therapy in 
2004, chloroquine + sulfadoxine/pyrimethamine has been used for the treatment of 
uncomplicated malaria. To assess the distribution of pfcrt, pfmdr1, dhfr, and dhps genotypes 
in Plasmodium falciparum, we conducted hospital- and community-based surveys in 
Bandarban, Bangladesh (near the border with Myanmar) in 2007 and 2008. Using nested PCR 
followed by digestion, 139 P. falciparum isolates were genotyped. We found fixation of a 
mutation at position 76 in pfcrt and low prevalence of a mutation at position 86 in pfmdr1. In 
dhfr, a quadruple mutant which is the highest pyrimethamine-resistant genotype was found in 
19% of isolates, which is a significantly higher prevalence than reported in a previous study in 
Khagrachari (1%) in 2002. Microsatellite haplotypes flanking dhfr of the quadruple mutants 
in Bangladesh were identical or very similar to those found in Thailand and Cambodia, 
indicating a common origin for the mutant in these countries. These observations suggest that 
the higher prevalence of the dhfr quadruple mutant in Bandarban is because of parasite 
migration from Myanmar. However, continuous use of sulfadoxine/pyrimethamine would 
have also played a role through selection for the dhfr quadruple mutant. These results indicate 
an urgent need to collect molecular epidemiological information regarding dhfr and dhps 
genes, and a review of current sulfadoxine/pyrimethamine usage with the aim of avoiding the 
widespread distribution of high levels of resistant parasites in Bangladesh. 
 
Keywords: Plasmodium falciparum, sulfadoxine/pyrimethamine, dhfr, dhps, Bangladesh, 
microsatellite 
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Introduction 
 
The spread of drug resistance is one of the major challenges of combating malaria in 
endemic regions. Until recently, many countries used sulfadoxine/pyrimethamine (SP) either 
as a monotherapy or in combination with other antimalarials because of the increase of 
chloroquine (CQ) resistance. However, Plasmodium falciparum has already exhibited 
resistance to SP in most Asian, South American, and African countries where it has been 
intensively used [1]. 
A genetic cross-analysis has shown that CQ resistance is associated with a point 
mutation from lysine to threonine at position 76 (K76T) in pfcrt [2]. A substitution from 
asparagine to tyrosine at position 86 (N86Y) in pfmdr1 has been also reported to play some 
role in chloroquine resistance [3, 4]. Resistance to SP is associated with mutations in the 
dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) genes. In dhfr, point 
mutations at positions 51, 59, 108, and 164 are associated with pyrimethamine resistance [5-
7]. The first mutation exclusively occurs at position 108, while additional mutations at other 
positions are associated with a stepwise increase of pyrimethamine resistance. Importantly, 
isolates harboring mutations at these four positions (IRNL at positions 51, 59, 108, and 164 
with mutations underlined) show the highest pyrimethamine resistance [7]. Similarly, in dhps, 
mutations at positions 436, 437, 540, 581, and 613 are linked with sulfadoxine resistance in a 
stepwise manner [8, 9]. 
In Bangladesh, 84,690 confirmed malaria cases were reported in 2008, more than 80% of 
which were reported from the greater Chittagong Hill Tracts and neighboring Cox’s Bazar 
districts [10]. The predominant species is P. falciparum at 75% of cases [10]. A combination 
of CQ and primaquine had been used as a first-line antimalarial for the treatment of 
uncomplicated malaria. SP was prescribed as a second-line treatment in combination with 
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quinine. However, the level of adequate clinical response to CQ was reported as only 34% in 
1996-7 [11]. Similarly, failure of SP + quinine treatment also reached unacceptable levels 
(17%) by 2002 [12]. In 2004, artemisinin combination therapy (ACT) was officially 
introduced as the first-line treatment for confirmed P. falciparum cases. In the later half of 
2007, it has been implemented in the health facilities in rural areas. However, despite the high 
prevalence of resistance, CQ + SP has been adopted in the national guidelines for treating 
presumptive malaria cases. 
To date, only one molecular epidemiological study has been reported in Bangladesh, and 
it found that the highest pyrimethamine-resistant genotype, the dhfr quadruple mutant, was of 
considerably low prevalence (1%) in Khagrachari in 2002 [12]. Herein, we report the 
distribution of dhfr, dhps, pfcrt, and pfmdr1 genotypes in P. falciparum isolates from 
Bandarban, where SP and CQ have been used in the rural area. Bandarban is located about 
200 km south from the previous study site, Khagrachari. Khagrachari shares a border with 
India, whereas Bandarban borders Myanmar, where antimalarial-resistant parasites are widely 
distributed. In these geographical settings, we also considered how migration has affected the 
distribution of dhfr, dhps, pfcrt, and pfmdr1 genotypes. 
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Materials and Methods 
 
2.1 Study site 
 
A hospital-based survey was conducted at Bandarban district hospital from October to 
December 2007 (Figure 1). We also carried out a community-based survey at six malaria-
endemic villages in Bandarban in March 2008; namely, Sultanpur, Chemidalupara, Kyaching 
ghata natun para, Saingya daneshpara, Faruqpara, and Empupara. Bandarban is a hilly district 
located in the eastern part of the country bordering Myanmar. The majority Bengalis and an 
additional 11 different indigenous ethnic minorities live in this district. A majority of the 
inhabitants are farmers, forest workers, daily workers in development projects, and rubber 
plantation workers. In Bandarban, malaria is moderately endemic with perennial but 
seasonally intense transmission during pre- and post-monsoon periods (May-July and 
September-October). P. falciparum (75%) and P. vivax (25%) are the two most prevalent 
parasites reported from this district [10]. P. malariae has also been occasionally found. The 
principal vectors are Anopheles dirus, A. minimus, and A. phillipinensis. 
 
2.2 Patients 
 
In both hospital- and community-based surveys, patients were screened by a rapid 
diagnostic test using paracheque F (Orchid Biomedical System, Verna, Goa, India) and 
samples were also microscopically examined by two expert microscopists. Seventy-five 
microliters of blood were collected from all enrolled study subjects by heparinized capillary 
tube, and blotted onto 31ETCHR filter paper (Whatman International Ltd., Kent, UK). Blood 
on the filter papers was dried at room temperature and then transported to the Tokyo 
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Women’s Medical University for molecular analysis. In the hospital-based survey, patients 
were mainly treated with Artemether + Lumefantrine or quinine for 7 days. In cases of severe 
malaria, intravenous administration of quinine was used. In the community-based survey, P. 
falciparum cases were treated with quinine for 7 days, while CQ + primaquine was used for P. 
vivax cases. 
Before enrollment, written informed consent was obtained from all study subjects. In the 
case of children, consent was obtained from a legal guardian. This study was approved by the 
Bangladesh Medical Research Council and the local health regulatory body in Bandarban, 
Bangladesh. 
 
2.3 Species-specific PCR and genotyping of dhfr, dhps, pfcrt, and pfmdr1 
 
Parasite DNA was extracted from a quarter of the blood blotted on the filter paper using 
a DNA extraction kit (QIAGEN QIAmp DNA Mini Kit Catalog 51304, Germany) according 
to the manufacturer’s instructions. To confirm the species identification, species-specific PCR 
was carried out on all positive and suspected cases as previously described [13]. 
Polymorphisms in dhfr at positions 51, 59, 108, and 164, and in dhps at positions 436, 437, 
540, 581, and 613 were assessed by nested PCR followed by restriction digestion as described 
by Duraisingh et al. [14]. In pfcrt, the K76T polymorphism was assessed as described by 
Djimdé et al. [15]. In pfmdr1, polymorphisms at positions 86, 184, 1034, 1042, and 1246 were 
assessed by nested PCR, followed by restriction digestion as described by Duraisingh et al. 
[4]. 
 
2.4 Microsatellite haplotypes flanking dhfr 
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In isolates harboring the quadruple mutant in dhfr, nucleotide length variations 
(determined by the number of TA repeats) of microsatellite markers were determined to infer 
the origin of the mutants. We measured three microsatellite markers located at 0.1 kb and 3.87 
kb upstream and 1.48 kb downstream of the dhfr locus as described by Nair et al. [16]. In 
brief, semi-nested PCR was performed using fluorescent end-labeled primers. Size variations 
of the amplified products were determined by electrophoresis on an ABI 377 and analyzed 
with Genescan software (Applied Biosystems, CA, USA). In the event of two or more 
polymorphisms being detected, we considered these isolates as mixed infections. The 
microsatellite haplotypes of samples from the present study were compared to those we 
previously reported in isolates harboring a dhfr quadruple mutant in Thailand and Cambodia 
[17]. 
 
2.5 Statistical analysis 
 
Chi-square test, Fisher’s exact test, and Student’s t-test were carried out using JMP Ver 8 
(SAS Institute Inc., NC, USA). Probability (P) values of less than 0.05 were considered to be 
statistically significant. 
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Results 
 
3.1 Patients’ background 
 
In the community-based survey at six villages, malaria infection was found in 2.9% 
(30/1043) of individuals. These positive cases were confirmed by species-specific PCR: P. 
falciparum (n = 11), P. vivax (n = 16), and P. falciparum + P. vivax (n = 3). In the hospital-
based survey, agreement to participate in this study was secured from 132 malaria-infected 
patients. Infection in these cases was also confirmed by species-specific PCR: P. falciparum 
(n = 128), P. vivax (n = 2), and P. falciparum + P. vivax (n = 2). Thus, a total of 139 P. 
falciparum blood samples were used for the molecular analysis (Table 1).  
 
3.2 Mutations in dhfr, dhps, pfcrt, and pfmdr1 
 
We did not find any significant differences in genotype prevalence in dhfr, dhps, pfcrt, 
and pfmdr1 between the hospital- and community-based surveys (Supplementary Table 1), 
and thus the two groups were combined for subsequent analysis. A mixture of wild-type and 
mutant alleles was observed within some infections at positions 51 (n = 6) and 164 (n = 15) in 
dhfr, position 76 in pfcrt (n = 10), and positions 86 (n = 15) and 184 (n =5) in pfmdr1. These 
were excluded from subsequent analysis. In dhfr, a mutation at position 108 (S108N), which 
is believed to be the initial mutation for pyrimethamine resistance, was observed in all studied 
isolates (Table 2). I164L, the mutation that confers the highest pyrimethamine resistance, was 
detected in 21.8% of studied isolates. In dhps, 83.4% of the study isolates carried a mutation 
at position 437, which has been reported as the initial mutation for sulfadoxine resistance in 
many endemic regions. In pfcrt, all isolates harbored the K76T mutation. In pfmdr1, a 
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mutation at position 86 (N86Y) only was detected in 23.4% of isolates. No mutation was 
detected at positions 1034, 1042, or 1246. 
 
3.3 Genotypes of dhfr, dhps, and pfmdr1 
 
In dhfr, we detected six mutant genotypes: NCNI, NRNI, ICNI, NRNL, IRNI, and IRNL 
(amino acids at positions 51, 59, 108, and 164, mutations underlined) (Table 3). Nearly 50% 
of isolates were double mutants and most of these were NRNI. The other double mutant, ICNI, 
was found in only two isolates. Among the two types of triple mutants, IRNI was the major 
genotype (26.9%). The other triple mutant (NRNL) was found at a prevalence of 3.4%. The 
quadruple mutant (IRNL) that confers the highest level of pyrimethamine resistance was 
found at a prevalence of 19.3%. Only one isolate was a single mutant (NCNI). None of the 
samples harbored the wild genotype. In dhps, we detected nine distinct genotypes: three forms 
of triple mutant (AGEAA, SGEGA, and AGKGA (amino acids at positions 436, 437, 540, 
581, and 613, mutations underlined), three forms of double mutant (AGKAA, SGEAA, and 
SGKGA), two forms of single mutant (AAKAA and SGKAA), and the wild-type SAKAA 
(Table 3). Nearly 50% of the isolates were triple mutants. The most prevalent triple mutant 
was AGEAA (37.4%), followed by SGEGA (8.6%). Among the three forms of double mutant, 
the two major genotypes were SGEAA (15.9%) and SGKGA (10.8%). The wild-type was 
detected in 15.9% of the study isolates. In pfmdr1, we detected three genotypes: YYSNN, 
NFSNN, and NYSNN (amino acids at positions 86, 184, 1034, 1042, and 1246, mutations 
underlined). Wild-type NYSNN was the most prevalent (63.7%). 
 
3.4 Microsatellite haplotypes flanking dhfr in quadruple mutants 
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We successfully determined microsatellite haplotypes flanking dhfr in 21 isolates 
harboring dhfr quadruple mutants in Bangladesh (Table 4). Only two haplotypes were 
observed: 194/176/106 (n = 20) and 194/176/108 (n = 1). These were compared to our 
previous results in Cambodia and Thailand [17]. In all three countries, all parasites harboring 
the dhfr quadruple mutant shared identical or very similar microsatellite haplotypes, 
suggesting a common origin of the dhfr quadruple mutant. 
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Discussion 
 
In the present study, in Bandarban, Bangladesh, the highest pyrimethamine-resistant 
genotype of dhfr, the quadruple mutant, was found in 19% of isolates. This is significantly 
higher than reported in a previous study in Khagrachari in 2002 (1%) [12]. It is possible that 
the high prevalence of the dhfr quadruple mutant in Bandarban is due to selection for this 
mutant because of continuing SP usage. Although ACT was officially introduced as the first-
line treatment for confirmed P. falciparum cases in Bangladesh in 2004, it did not become 
widely available in Bandarban until the later half of 2007, just before the present survey. In 
addition, an antimalarial combination of CQ and SP is still widely used for treatment of 
presumptive P. falciparum cases. These two antimalarials are also easily available at many 
retail stores without a prescription. Thus, continuous SP use in Bandarban might have played 
a role in the high prevalence of the quadruple mutant.  
In addition to selection due to SP use, parasite migration from Myanmar to Bandarban 
may also have contributed the high prevalence of the dhfr quadruple mutant in Bandarban. It 
has recently been indicated that dhfr quadruple mutants have had a single origin in Southeast 
Asia, putatively at the Thai/Cambodia border, and then spread to other Southeast Asian 
endemic regions [16, 17]. We found identical or very similar patterns of microsatellite 
haplotypes flanking dhfr among isolates from Bandarban, Thailand, and Cambodia, strongly 
suggesting a common origin of the quadruple mutants in these regions. At present, the 
prevalence of dhfr quadruple mutants is highest in Thailand (80%) followed by Cambodia 
(40%) [16, 17]. In Myothugy, on the western border of Myanmar, 29% of isolates harbored 
this genotype [16]. Although most of the malaria-endemic districts in Bangladesh, including 
Khagrachari, border with India, Bandarban borders Myanmar. Recently, mass human 
migration has occurred from Myanmar to Bangladesh; i.e., Rohingya refugees fleeing to 
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Bandarban and Cox’s Bazar. Thus, these findings support the hypothesis of gene flow in the 
parasites from Thai/Cambodia to Bandarban, putatively through Myanmar.  
The prevalence of mutant dhps alleles in the present study (84%) is similar to that in 
Myanmar in 2000 (>75%) [18], but higher than that in India (36% in 2003-4) [19]. This might 
also be explained by gene flow of resistant parasites from Myanmar to Bangladesh, and then 
to India. However, in Bandarban, high sulfadoxine-resistant triple mutant genotypes of dhps 
were found in 47% of isolates, which is lower than in Thailand (nearly 90%), Cambodia 
(70%), and Myanmar (55-60%) [18]. If SP is widely and continuously used in Bandarban, the 
prevalence of sulfadoxine-resistant genotypes will eventually be similar to that observed in 
the high SP-resistant countries. 
The K76T mutation in pfcrt has already been fixed in Bandarban, and the prevalence is 
similar to that found in a previous study in Khagrachari (94%) [12]. This is consistent with 
the high prevalence of both in vitro (84%) and in vivo (66%) resistance to CQ previously 
reported from Bangladesh [11, 20]. A similar fixation of the pfcrt K76T mutation is also 
observed in neighboring countries like India, Myanmar, and Thailand [18, 21]. 
In Bandarban, the prevalence of the pfmdr1 N86Y mutation was 24%, which is lower 
than in Khagrachari in 2002 (70%) [12], and lower than in Assam in India, which is about 400 
km north of the present study site (66% in 2000-1 and 2003-4 [22] and 69% in 2006 [23]). 
However, these studies cannot be directly compared because of differences in time and 
location. The N86Y mutation plays a role in CQ resistance to some extent [24, 25]. In 
addition, it has been reported that complete withdrawal of CQ usage in the community can 
lead to decreased prevalence of the N86Y mutation [26]. However, in Bandarban, CQ was 
still widely used in the community at the time of the present study. In contrast to the 
relationship with CQ, the N86Y mutation is linked to increased sensitivity to artemisinin [4, 
27]. In Zanzibar, after treatment with Artemether + Lumefantrine, the prevalence of the N86Y 
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mutation significantly decreased from 83% in pre-treatment patients to 56% in recurrent 
patients [27]. However, at the time of the present study, ACT was not widely-distributed in 
Bandarban, and thus ACT could not have strongly influenced the observed low prevalence of 
the N86Y mutation. Increased susceptibility to mefloquine has also been associated with the 
N86Y mutation [4, 28, 29]. In Bangladesh, a high prevalence (61%) of in vitro resistance to 
mefloquine was reported from the neighboring district of Cox’s Bazar in 1999 [20]. Thus, the 
high frequency of mefloquine resistance might be associated with the observed low 
prevalence of the N86Y mutation in the present study. However, in Bangladesh, mefloquine 
has never been officially registered and has rarely been used for the treatment of CQ 
resistance cases. Mefloquine resistance has already been observed in Southeast Asian 
countries where, similar to the present result, the N86Y mutation is less frequently (<30%) 
observed [18, 30]. Taken together, these findings suggest that mefloquine-resistant parasites 
have migrated from these regions to Bandarban, Bangladesh. However, the increase in the 
pfmdr1 copy number is also a key determinant for mefloquine resistance [31, 32], and thus, 
determination of the copy number in pfmdr1 in the present isolates is planned.  
In conclusion, we found a high prevalence of the quadruple mutant of dhfr in Bandarban. 
We also detected a low prevalence of the N86Y mutation in pfmdr1. Migration of SP- and 
mefloquine-resistant parasites to Bandarban explains the observed findings. In Bangladesh, 
SP is still used for uncomplicated presumptive malaria cases. Continued use of SP would 
accelerate the current progression of drug resistance [33]. Thus, there is an urgent need to 
collect molecular epidemiological information regarding drug resistance-related genes. The 
current usage of SP for treatment of presumptive malaria cases also needs to be reviewed. 
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Figure legends 
 
Figure 1. Map of study sites in Bandarban, Bangladesh. 
The map shows the greater Chittagong Hill Tracts (Bandarban, Khagrachari, and Rangamati) 
and Cox’s Bazar districts. Bandarban borders Myanmar in the south and southeast. All 
neighboring districts are malaria-endemic. 
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N
S
Hospital Community 
(n = 128)  (n = 11)
Gender
Male 86 6
Female 42 5
Age (years)
<5 years 10 2
5-14 years 33 6
≥15 years 85 3
Splenomegaly (%) 27.2 18.2
Median parasite density (µL-1) 27159 6020
(25 percentile, 75 percentile) (12383, 85970) (815, 11465)
Table 1. Charactersistics of Plasmodium falciparum- infected patients from
hospital-based (n = 128) and community-based (n = 11) studies in Bandarban,
Bangladesh
Gene na
(Wild-type/Mutant)
dhfr
51 133 N/I 69 (51.9) 64 (48.1)
59 139 C/R 2 (1.4) 137 (98.6)
108 139 S/N 0 (0.0) 139 (100)
164 124 I/L 97 (78.2) 27 (21.8)
dhps
436 139 S/A 80 (57.6) 59 (42.4)
437 139 A/G 23 (16.6) 116 (83.4)
540 139 K/E 53 (38.1) 86 (61.9)
581 139 A/G 111 (79.9) 28 (20.1)
613 139 A/S 139 (100) 0 (0.0)
pfcrt
76 129 K/T 0 (0.0) 129 (100)
pfmdr1
86 124 N/Y 95 (76.6) 29 (23.4)
184 134 Y/F 118 (88.1) 16 (11.9)
1034 139 S/C 139 (100) 0 (0.0)
1042 139 N/D 139 (100) 0 (0.0)
1246 139 D/Y 139 (100) 0 (0.0)
a; Mixed infections were excluded.
Table 2. Prevalence of dhfr , dhps , pfcrt, and pfmdr1 mutations in 139 P.
falciparum  isolates from Bandarban, Bangladesh
Wild-type (%) Mutant (%)
Amino Acid
Genesa Genotypes
dhfr (n=119) IRNLb 23 (19.3)
IRNI 32 (26.9)
NRNL 4 (3.4)
ICNI 2 (1.7)
NRNI 57 (47.9)
NCNI 1 (0.8)
dhps (n=139) AGEAAc 52 (37.4)
SGEGA 12 (8.6)
AGKGA 1 (0.7)
AGKAA 5 (3.6)
SGEAA 22 (15.8)
SGKGA 15 (10.8)
AAKAA 1 (0.8)
SGKAA 9 (6.5)
SAKAA 22 (15.8)
pfmdr1 (n=121) YYSNNd 29 (23.9)
NFSNN 15 (12.4)
NYSNN 77 (63.7)
d; Amino acids at positions 86, 184, 1034, 1042, and
1246 with mutations underlined
b; Amino acids at positions 51, 59, 108, and 164
with mutations underlined
c; Amino acids at positions 436, 437, 540, 581, and
613 with mutations underlined
Table 3. Prevalence of dhfr , dhps,  and pfmdr1
genotypes in P. falciparum  isolates from Bandarban,
Bangladesh
n (%)
a; In pfcrt , only position 76 was determined.
Country
194/176/106 194/176/108 194/178/106
Bangladesh 20 1 0
Cambodiab 14 0 0
Thailandb 41 0 3
a; size (bp) of microsatellite markers (-0.1 kb/-3.87 kb/+1.48 kb flanking dhfr )
b; Data from ref [17].
Microsatellite haplotypea
 Table 4. Microsatellite haplotypes around dhfr in P. falciparum  isolates
harboring the dhfr quartet mutation from Bangladesh (n = 21), Cambodia (n =
14), and Thailand (n = 44)
Genea Genotypes Hospital Community
dhfr IRNLb 21 2
(n=119) IRNI 29 3
NRNL 4 0
NRNI 54 3
ICNI 2 0
NCNI 1 0
dhps AGEAAc 45 7
(n=139) SGEGA 12 0
AGKGA 0 1
AGKAA 5 0
SGEAA 21 1
SGKGA 15 0
AAKAA 1 0
SGKAA 8 1
SAKAA 21 1
pfmdr1 YYSNNd 26 3
(n=121) NFSNN 15 0
NYSNN 70 7
a; Mixed infections were excluded. In pfcrt , position 76 alone was determined.
b; Amino acid at positions 51, 59, 108 and 164 with mutations underlined.
c; Amino acid at positions 436, 437, 540, 581 and 613 with mutations underlined.
d; Amino acid at positions 86, 184, 1034, 1042 and 1246 with mutations underlined.
Suplementary Table 1. dhfr , dhps  and pfmdr1 genotypes in Plasmodium
falciparum  isolates in community-based (n = 11) and hospital-based (n = 128)
survey in Bandarban, Bangladesh
